1
|
Katsikitis M, Lane BR, Ozols I, Statham D. Consumer and carer perspectives in the development of a mental health research, treatment and teaching facility: A thematic analysis. J Psychiatr Ment Health Nurs 2017; 24:534-544. [PMID: 28449291 DOI: 10.1111/jpm.12394] [Citation(s) in RCA: 4] [Impact Index Per Article: 0.6] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Accepted: 04/24/2017] [Indexed: 01/29/2023]
Abstract
UNLABELLED WHAT IS KNOWN ON THE SUBJECT?: Around the world, recovery has become a focus in mental health policy. The participation of people accessing mental health services (consumers) and carers of such individuals in decision-making related to services forms part of this recovery orientation and studies suggest positive outcomes following such participation. However, little is known about consumer and carer desires at the earliest stages of development of new services. WHAT THIS PAPER ADDS TO EXISTING KNOWLEDGE?: Consumers and carers desire changes to how mental health services are provided. Many factors affect consumer and carer experiences, including language use, physical design of spaces, accessibility, consideration of individual needs, practical help and how well care is continued from hospital to community settings. Carers may feel sidelined in treatment and be distressed as a result. They wish to be respected and involved in recovery. Consumers and carers wish for focus on broader health, with care taken to address physical health, psychological needs, social needs and treatment of the whole person rather than just an illness. WHAT ARE THE IMPLICATIONS FOR PRACTICE?: Consumers and carers desire partnership with professionals in recovery. Tokenistic participation should be avoided. Flexibility in how services are provided and less formality may help engage consumers and carers. Specifically, professionals may help by linking consumers and carers to services that address practical needs. Professionals should communicate with carers to draw on their expertise about the individual accessing the mental health service and help carers understand how they can assist the individual's recovery. ABSTRACT Introduction Recovery-oriented mental health policies recognize consumer and carer participation in service decision-making as essential, but little is known about the views of these individuals in the earliest stages of service development. Aim This study sought consumer and carer perspectives addressing the establishment of a mental health research, treatment and teaching facility in their region. Methods Two 2-hr focus groups were conducted, with separate groups held for mental health consumers (n = 9) and carers (n = 9), respectively. Discussions pertained to mental health literacy, gaps in current services, desires for an ideal facility (in terms of physical design and services offered) and what would help in recovery. Results Inductive thematic analysis was used to generate three themes: care outside of consultations, carer involvement in recovery and holistic approaches to mental health care. Consumers desired a facility that could cater to individual needs. Carers felt excluded in recovery and unable to provide effective support. Both groups preferred holistic approaches to mental health, expressing ambivalence towards medication and hospitalization. Discussion Consumers and carers have many needs that conventional practices may not meet. Implications for practice They have clear desires for equal partnership in recovery and for transformation of conventional treatment methods.
Collapse
Affiliation(s)
- M Katsikitis
- School of Social Sciences, University of the Sunshine Coast, Maroochydore DC, QLD, Australia
| | - B R Lane
- School of Social Sciences, University of the Sunshine Coast, Maroochydore DC, QLD, Australia
| | - I Ozols
- Mental Health at Work, Melbourne, VIC, Australia.,Department of Psychiatry, University of Melbourne, Parkville, VIC, Australia
| | - D Statham
- School of Social Sciences, University of the Sunshine Coast, Maroochydore DC, QLD, Australia
| |
Collapse
|
2
|
Lane BR, Russo P, Uzzo R, Hernandez AV, Boorjian SA, Thompson RH, Fergany AF, Love T, Campbell S. Use of comparison of cold and warm ischemia during partial nephrectomy in 660 solitary kidneys to investigate the role of nonmodifiable factors in determining ultimate renal function. J Clin Oncol 2011. [DOI: 10.1200/jco.2011.29.7_suppl.321] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/20/2022] Open
Abstract
321 Background: Factors that determine renal function after partial nephrectomy (PN) are not well defined, including the impact of cold vs. warm ischemia and the relative importance of modifiable and non-modifiable factors. We studied these determinants in a large cohort of patients with a solitary functioning kidney undergoing PN. Methods: In 1980–2009, 660 PN were performed at 4 centers for tumor in a solitary-functioning kidney under cold (n=300) or warm (n=360) ischemia. Data were collected in IRB-approved registries; follow- up averaged 4.5 years. Pre- and postoperative glomerular filtration rates (GFR) were estimated via CKD-EPI equation. Results: At 3 months after PN, median GFR decreased by equivalent amounts with cold or warm ischemia (21% vs. 22%, respectively, p=0.7) although median cold ischemic times were much longer (45 vs. 22 min. respectively, p<0.001). In multivariable analyses, increasing age, larger tumor size, lower preoperative GFR, and longer ischemia time were associated with decreased postoperative GFR (p<0.05). When percentage of parenchyma spared was incorporated into the analysis, this factor and preoperative GFR proved to be the primary determinants of ultimate renal function, and duration of ischemia lost statistical significance. Conclusions: This non-randomized comparative study suggests that long-term renal function after PN is determined primarily by the quantity and quality of renal parenchyma that can be preserved. Within the relatively strict parameters of conventional practice, i.e. predominantly short ischemic intervals and liberal use of hypothermia, ischemia time was not an independent predictor of ultimate renal function after PN. Nevertheless, type and duration of ischemia remain the most important modifiable factors during PN, and mandate further study. [Table: see text]
Collapse
Affiliation(s)
- B. R. Lane
- Spectrum Health, Michigan State University, Grand Rapids, MI; Memorial Sloan-Kettering Cancer Center, New York, NY; Fox Chase Cancer Center, Philadelphia, PA; Cleveland Clinic, Cleveland, OH; Mayo Clinic, Rochester, MN; MetroHealth Medical Center, Cleveland, OH; Glickman Urological and Kidney Institute Cleveland Clinic, Cleveland, OH
| | - P. Russo
- Spectrum Health, Michigan State University, Grand Rapids, MI; Memorial Sloan-Kettering Cancer Center, New York, NY; Fox Chase Cancer Center, Philadelphia, PA; Cleveland Clinic, Cleveland, OH; Mayo Clinic, Rochester, MN; MetroHealth Medical Center, Cleveland, OH; Glickman Urological and Kidney Institute Cleveland Clinic, Cleveland, OH
| | - R. Uzzo
- Spectrum Health, Michigan State University, Grand Rapids, MI; Memorial Sloan-Kettering Cancer Center, New York, NY; Fox Chase Cancer Center, Philadelphia, PA; Cleveland Clinic, Cleveland, OH; Mayo Clinic, Rochester, MN; MetroHealth Medical Center, Cleveland, OH; Glickman Urological and Kidney Institute Cleveland Clinic, Cleveland, OH
| | - A. V. Hernandez
- Spectrum Health, Michigan State University, Grand Rapids, MI; Memorial Sloan-Kettering Cancer Center, New York, NY; Fox Chase Cancer Center, Philadelphia, PA; Cleveland Clinic, Cleveland, OH; Mayo Clinic, Rochester, MN; MetroHealth Medical Center, Cleveland, OH; Glickman Urological and Kidney Institute Cleveland Clinic, Cleveland, OH
| | - S. A. Boorjian
- Spectrum Health, Michigan State University, Grand Rapids, MI; Memorial Sloan-Kettering Cancer Center, New York, NY; Fox Chase Cancer Center, Philadelphia, PA; Cleveland Clinic, Cleveland, OH; Mayo Clinic, Rochester, MN; MetroHealth Medical Center, Cleveland, OH; Glickman Urological and Kidney Institute Cleveland Clinic, Cleveland, OH
| | - R. H. Thompson
- Spectrum Health, Michigan State University, Grand Rapids, MI; Memorial Sloan-Kettering Cancer Center, New York, NY; Fox Chase Cancer Center, Philadelphia, PA; Cleveland Clinic, Cleveland, OH; Mayo Clinic, Rochester, MN; MetroHealth Medical Center, Cleveland, OH; Glickman Urological and Kidney Institute Cleveland Clinic, Cleveland, OH
| | - A. F. Fergany
- Spectrum Health, Michigan State University, Grand Rapids, MI; Memorial Sloan-Kettering Cancer Center, New York, NY; Fox Chase Cancer Center, Philadelphia, PA; Cleveland Clinic, Cleveland, OH; Mayo Clinic, Rochester, MN; MetroHealth Medical Center, Cleveland, OH; Glickman Urological and Kidney Institute Cleveland Clinic, Cleveland, OH
| | - T. Love
- Spectrum Health, Michigan State University, Grand Rapids, MI; Memorial Sloan-Kettering Cancer Center, New York, NY; Fox Chase Cancer Center, Philadelphia, PA; Cleveland Clinic, Cleveland, OH; Mayo Clinic, Rochester, MN; MetroHealth Medical Center, Cleveland, OH; Glickman Urological and Kidney Institute Cleveland Clinic, Cleveland, OH
| | - S. Campbell
- Spectrum Health, Michigan State University, Grand Rapids, MI; Memorial Sloan-Kettering Cancer Center, New York, NY; Fox Chase Cancer Center, Philadelphia, PA; Cleveland Clinic, Cleveland, OH; Mayo Clinic, Rochester, MN; MetroHealth Medical Center, Cleveland, OH; Glickman Urological and Kidney Institute Cleveland Clinic, Cleveland, OH
| |
Collapse
|
3
|
Wood L, Garcia JA, Elson P, Salas RN, Lane BR, Klein E, Stephenson A, Dreicer R, Campbell SC, Rini BI. Sunitinib in patients (pts) with unresectable primary renal cell carcinoma (RCC). J Clin Oncol 2009. [DOI: 10.1200/jco.2009.27.15_suppl.5096] [Citation(s) in RCA: 7] [Impact Index Per Article: 0.5] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/20/2022] Open
Abstract
5096 Background: Sunitinib inhibits VEGF and related receptors, with high tumor shrinkage rates in metastatic (met) RCC. Shrinkage of primary tumors has been observed, although prospective investigation is lacking. The ability of sunitinib to convert primary RCC tumors from unresectable to resectable is of high clinical interest. Methods: Pts with histologically-confirmed RCC with an unresectable primary tumor with or without met disease were enrolled on a single-arm phase II trial. Primary tumors were unresectable due to ≥ 1 of the following: large tumor size, bulky lymphadenopathy, encasement of renal vessels, IVC thrombosis or proximity to vital structures. Pts received 50 mg sunitinib continuous dosing in repeated 6-week cycles. Staging by CT scans or MRI was done at baseline and every 2 cycles. A Simon 2-stage design was employed to test the alternative hypothesis of a conversion to resectability rate of 20% versus the null hypothesis of 5%; β = 0.8, α = 0.05 (n = 31). Results: 18 pts have been enrolled; 1 excluded due to a non-RCC diagnosis. Pts were unresectable due to bulky lymphadenopathy (6), IVC thrombosis (4), proximity to vital structures (4) or tumor size (3), although most pts had multiple factors. Median age among 14 evaluable pts was 61 years (range, 37–80), 59% male, 76% ECOG PS 0; 79% had distant met disease. The 14 evaluable pts have received a median of 3 cycles of therapy (range, 1–10+). Three pts (21%) have undergone primary tumor resection; viable RCC was identified in all specimens with no unexpected surgical morbidity. Nine pts (53%) had primary tumor reduction (median 19%; range, -64% to -1%). Overall, median best % change in tumor burden was 4.9% reduction for primary tumors (range, -43.1% to +8.5%) and 10.7% reduction for met sites (range, -89.5% to +28.6%). Median PFS is 4.9 months. Eleven pts (79%) discontinued therapy; 8 for PD, 1 for adverse events and 2 following surgery which removed all visible disease. Eight pts (57%) experienced grade 3 toxicity including thrombocytopenia, fatigue, hypertension, anemia, hemoptysis, and hand-foot syndrome; 1 pt had grade 4 neutropenia. Conclusions: Sunitinib has activity in unresectable primary RCC tumors, permitting resection in some pts. Continued prospective investigation is required to optimize patient selection and timing of surgery. [Table: see text]
Collapse
Affiliation(s)
- L. Wood
- Cleveland ClinicTaussig Cancer Institute, Cleveland, OH; Cleveland Clinic Glickman Urological Institute, Cleveland, OH
| | - J. A. Garcia
- Cleveland ClinicTaussig Cancer Institute, Cleveland, OH; Cleveland Clinic Glickman Urological Institute, Cleveland, OH
| | - P. Elson
- Cleveland ClinicTaussig Cancer Institute, Cleveland, OH; Cleveland Clinic Glickman Urological Institute, Cleveland, OH
| | - R. N. Salas
- Cleveland ClinicTaussig Cancer Institute, Cleveland, OH; Cleveland Clinic Glickman Urological Institute, Cleveland, OH
| | - B. R. Lane
- Cleveland ClinicTaussig Cancer Institute, Cleveland, OH; Cleveland Clinic Glickman Urological Institute, Cleveland, OH
| | - E. Klein
- Cleveland ClinicTaussig Cancer Institute, Cleveland, OH; Cleveland Clinic Glickman Urological Institute, Cleveland, OH
| | - A. Stephenson
- Cleveland ClinicTaussig Cancer Institute, Cleveland, OH; Cleveland Clinic Glickman Urological Institute, Cleveland, OH
| | - R. Dreicer
- Cleveland ClinicTaussig Cancer Institute, Cleveland, OH; Cleveland Clinic Glickman Urological Institute, Cleveland, OH
| | - S. C. Campbell
- Cleveland ClinicTaussig Cancer Institute, Cleveland, OH; Cleveland Clinic Glickman Urological Institute, Cleveland, OH
| | - B. I. Rini
- Cleveland ClinicTaussig Cancer Institute, Cleveland, OH; Cleveland Clinic Glickman Urological Institute, Cleveland, OH
| |
Collapse
|
4
|
Lane BR, Lore K, Bock PJ, Andersson J, Coffey MJ, Strieter RM, Markovitz DM. Interleukin-8 stimulates human immunodeficiency virus type 1 replication and is a potential new target for antiretroviral therapy. J Virol 2001; 75:8195-202. [PMID: 11483765 PMCID: PMC115064 DOI: 10.1128/jvi.75.17.8195-8202.2001] [Citation(s) in RCA: 101] [Impact Index Per Article: 4.4] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Grants] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/20/2022] Open
Abstract
Production of the C-X-C chemokines interleukin-8 (IL-8) and growth-regulated oncogene alpha (GRO-alpha) in macrophages is stimulated by exposure to human immunodeficiency virus type 1 (HIV-1). We have demonstrated previously that GRO-alpha then stimulates HIV-1 replication in both T lymphocytes and macrophages. Here we demonstrate that IL-8 also stimulates HIV-1 replication in macrophages and T lymphocytes. We further show that increased levels of IL-8 are present in the lymphoid tissue of patients with AIDS. In addition, we demonstrate that compounds which inhibit the actions of IL-8 and GRO-alpha via their receptors, CXCR1 and CXCR2, also inhibit HIV-1 replication in both T lymphocytes and macrophages, indicating potential therapeutic uses for these compounds in HIV-1 infection and AIDS.
Collapse
Affiliation(s)
- B R Lane
- Divisions of Infectious Diseases, University of Michigan Medical Center, Ann Arbor, Michigan 48109-0640, USA
| | | | | | | | | | | | | |
Collapse
|
5
|
Lane BR, Strieter RM, Coffey MJ, Markovitz DM. Human immunodeficiency virus type 1 (HIV-1)-induced GRO-alpha production stimulates HIV-1 replication in macrophages and T lymphocytes. J Virol 2001; 75:5812-22. [PMID: 11390582 PMCID: PMC114296 DOI: 10.1128/jvi.75.13.5812-5822.2001] [Citation(s) in RCA: 28] [Impact Index Per Article: 1.2] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Grants] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 02/07/2023] Open
Abstract
We examined the early effects of infection by CCR5-using (R5 human immunodeficiency virus [HIV]) and CXCR4-using (X4 HIV) strains of HIV type 1 (HIV-1) on chemokine production by primary human monocyte-derived macrophages (MDM). While R5 HIV, but not X4 HIV, replicated in MDM, we found that the production of the C-X-C chemokine growth-regulated oncogene alpha (GRO-alpha) was markedly stimulated by X4 HIV and, to a much lesser extent, by R5 HIV. HIV-1 gp120 engagement of CXCR4 initiated the stimulation of GRO-alpha production, an effect blocked by antibodies to CXCR4. GRO-alpha then fed back and stimulated HIV-1 replication in both MDM and lymphocytes, and antibodies that neutralize GRO-alpha or CXCR2 (the receptor for GRO-alpha) markedly reduced viral replication in MDM and peripheral blood mononuclear cells. Therefore, activation of MDM by HIV-1 gp120 engagement of CXCR4 initiates an autocrine-paracrine loop that may be important in disease progression after the emergence of X4 HIV.
Collapse
Affiliation(s)
- B R Lane
- Department of Internal Medicine, Divisions of Infectious Diseases, University of Michigan Medical Center, Ann Arbor, MI 48109-0640, USA
| | | | | | | |
Collapse
|
6
|
Smith MJ, Gitlin SD, Browning CM, Lane BR, Clark NM, Shah N, Rainier S, Markovitz DM. GLI-2 modulates retroviral gene expression. J Virol 2001; 75:2301-13. [PMID: 11160733 PMCID: PMC114813 DOI: 10.1128/jvi.75.5.2301-2313.2001] [Citation(s) in RCA: 9] [Impact Index Per Article: 0.4] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Grants] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 03/01/2000] [Accepted: 12/07/2000] [Indexed: 11/20/2022] Open
Abstract
GLI proteins are involved in the development of mice, humans, zebrafish, Caenorhabditis elegans, Xenopus, and Drosophila. While these zinc finger-containing proteins bind to TG-rich promoter elements and are known to regulate gene expression in C. elegans and Drosophila, mechanistic understanding of how regulation is mediated through naturally occurring transcriptional promoters is lacking. One isoform of human GLI-2 appears to be identical to a factor previously called Tax helper protein (THP), thus named due to its ability to interact with a TG-rich element in the human T-lymphotropic virus type 1 (HTLV-1) enhancer thought to mediate transcriptional stimulation by the Tax protein of HTLV-1. We now demonstrate that, working through its TG-rich binding site and adjacent elements, GLI-2/THP actually suppresses gene expression driven by the HTLV-1 promoter. GLI-2/THP has no effect on the HTLV-2 promoter, activates expression from the promoters of human immunodeficiency virus types 1 and (HIV-1 and -2), and stimulates HIV-1 replication. Both effective suppression and activation of gene expression and viral replication require the first of the five zinc fingers, which is not necessary for DNA binding, to be intact. Thus, not only can GLI-2/THP either activate or suppress gene expression, depending on the promoter, but the same domain (first zinc finger) mediates both effects. These findings suggest a role for GLI-2 in retroviral gene regulation and shed further light on the mechanisms by which GLI proteins regulate naturally occurring promoters.
Collapse
Affiliation(s)
- M J Smith
- Department of Internal Medicine, University of Michigan Medical Center, Ann Arbor, Michigan 48109-0640, USA
| | | | | | | | | | | | | | | |
Collapse
|
7
|
Browning CM, Smith MJ, Clark NM, Lane BR, Parada C, Montano M, KewalRamani VN, Littman DR, Essex M, Roeder RG, Markovitz DM. Human GLI-2 is a tat activation response element-independent Tat cofactor. J Virol 2001; 75:2314-23. [PMID: 11160734 PMCID: PMC114814 DOI: 10.1128/jvi.75.5.2314-2323.2001] [Citation(s) in RCA: 6] [Impact Index Per Article: 0.3] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Grants] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 03/01/2000] [Accepted: 12/07/2000] [Indexed: 11/20/2022] Open
Abstract
Zinc finger-containing GLI proteins are involved in the development of Caenorhabditis elegans, Xenopus, Drosophila, zebrafish, mice, and humans. In this study, we show that an isoform of human GLI-2 strongly synergizes with the Tat transactivating proteins of human immunodeficiency virus types 1 and 2 (HIV-1 and -2) and markedly stimulates viral replication. GLI-2 also synergizes with the previously described Tat cofactor cyclin T1 to stimulate Tat function. Surprisingly, GLI-2/Tat synergy is not dependent on either a typical GLI DNA binding site or an intact Tat activation response element but does require an intact TATA box. Thus, GLI-2/Tat synergy results from a mechanism of action which is novel both for a GLI protein and for a Tat cofactor. These findings link the GLI family of transcriptional and developmental regulatory proteins to Tat function and HIV replication.
Collapse
Affiliation(s)
- C M Browning
- Department of Microbiology and Immunology, Ann Arbor, Michigan 48109-0640,USA
| | | | | | | | | | | | | | | | | | | | | |
Collapse
|
8
|
Lane BR, Markovitz DM, Woodford NL, Rochford R, Strieter RM, Coffey MJ. TNF-alpha inhibits HIV-1 replication in peripheral blood monocytes and alveolar macrophages by inducing the production of RANTES and decreasing C-C chemokine receptor 5 (CCR5) expression. J Immunol 1999; 163:3653-61. [PMID: 10490959] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Grants] [Subscribe] [Scholar Register] [Indexed: 02/14/2023]
Abstract
The pathogenesis of HIV-1 infection is influenced by the immunoregulatory responses of the host. Macrophages present in the lymphoid tissue are susceptible to infection with HIV-1, but are relatively resistant to its cytopathic effects and serve as a reservoir for the virus during the course of disease. Previous investigators have demonstrated that increased serum levels of TNF-alpha contribute to the clinical symptoms of AIDS and that TNF-alpha stimulates the production of HIV-1 in chronically infected lymphocytic and monocytic cell lines by increasing HIV-1 gene expression. Although previous studies have suggested that TNF-alpha may increase HIV-1 infection of primary human mononuclear cells, some recent studies have indicated that TNF-alpha suppresses HIV-1 infection of macrophages. We now demonstrate that TNF-alpha suppresses HIV-1 replication in freshly infected peripheral blood monocytes (PBM) and alveolar macrophages (AM) in a dose-dependent manner. As TNF-alpha has been shown to increase the production of C-C chemokine receptor (CCR5)-binding chemokines under certain circumstances, we hypothesized that TNF-alpha inhibits HIV-1 replication by increasing the expression of these HIV-suppressive factors. We now show that TNF-alpha treatment of PBM and AM increases the production of the C-C chemokine, RANTES. Immunodepletion of RANTES alone or in combination with macrophage inflammatory protein-1alpha and -1beta block the ability of TNF-alpha to suppress viral replication in PBM and AM. In addition, we found that TNF-alpha treatment reduces CCR5 expression on PBM and AM. These findings suggest that TNF-alpha plays a significant role in inhibiting monocytotropic strains of HIV-1 by two distinct, but complementary, mechanisms.
Collapse
Affiliation(s)
- B R Lane
- Department of Internal Medicine, Graduate Program in Cellular and Molecular Biology, School of Public Health, University of Michigan Medical Center, Ann Arbor 48109, USA
| | | | | | | | | | | |
Collapse
|
9
|
Kazanjian P, Locke AB, Hossler PA, Lane BR, Bartlett MS, Smith JW, Cannon M, Meshnick SR. Pneumocystis carinii mutations associated with sulfa and sulfone prophylaxis failures in AIDS patients. AIDS 1998; 12:873-8. [PMID: 9631140 DOI: 10.1097/00002030-199808000-00009] [Citation(s) in RCA: 112] [Impact Index Per Article: 4.3] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Grants] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 02/07/2023]
Abstract
BACKGROUND Failures of prophylaxis against Pneumocystis carinii pneumonia (PCP) in AIDS patients do occur, but no evidence for drug resistance has yet been presented. OBJECTIVE To determine whether mutations in the sulfa and sulfone drug target are associated with failure of prophylaxis using a sulfa-containing agent. METHODS Portions of the gene for P. carinii dihydropteroate synthase (DHPS), the sulfa and sulfone target, from 27 patients (20 of whom had AIDS) diagnosed with PCP between 1976 and 1997 were amplified using polymerase chain reaction and sequenced. Seven of the 27 patients (all of whom had AIDS) were receiving sulfa or sulfone drugs as prophylaxis for PCP. RESULTS Mutations were found at only two amino-acid positions and were significantly more common in patients who received sulfa/sulfone prophylaxis. Mutations were observed in five (71%) out of seven isolates from AIDS patients receiving sulfa/sulfone as prophylaxis compared with only two (15%) out of 13 specimens from AIDS patients who did not (P = 0.022). No mutations were seen in isolates from seven non-HIV-infected patients, none of whom were on prophylaxis. Mutations were only observed in specimens obtained in 1995-1997. CONCLUSIONS Mutations in two amino-acid positions were significantly more common in AIDS patients with PCP who failed sulfa/sulfone prophylaxis. These amino acids appeared to be directly involved in both substrate and sulfa binding, based on homology to the Escherichia coli DHPS crystal structure. Thus, the results were consistent with the possibility that mutations in the P. carinii DHPS are responsible for some of the failures of sulfa/sulfone prophylaxis in AIDS patients.
Collapse
Affiliation(s)
- P Kazanjian
- Department of Internal Medicine, University of Michigan, Ann Arbor 48109-0378, USA
| | | | | | | | | | | | | | | |
Collapse
|
10
|
Abstract
Previous genetic studies of the nematode Caenorhabditis elegans identified three important components of the cell death machinery. CED-3 and CED-4 function to kill cells, whereas CED-9 protects cells from death. Here CED-9 and its mammalian homolog Bcl-xL (a member of the Bcl-2 family of cell death regulators) were both found to interact with and inhibit the function of CED-4. In addition, analysis revealed that CED-4 can simultaneously interact with CED-3 and its mammalian counterparts interleukin-1beta-converting enzyme (ICE) and FLICE. Thus, CED-4 plays a central role in the cell death pathway, biochemically linking CED-9 and the Bcl-2 family to CED-3 and the ICE family of pro-apoptotic cysteine proteases.
Collapse
Affiliation(s)
- A M Chinnaiyan
- University of Michigan Medical School, Department of Pathology, Ann Arbor, MI 48109, USA
| | | | | | | |
Collapse
|
11
|
Abstract
Sulfa drugs are widely used in the treatment and prophylaxis of Pneumocystis carinii pneumonia. The nucleotide sequences of the sulfa target enzyme, dihydropteroate synthase (DHPS), differed substantially in human-, rat-, and mouse-derived P. carinii. Sequence variation also existed in the DHPSs from human-derived isolates. Six nucleotide changes were found in 6 human isolates; each was nonsynonymous and resulted in an amino acid change. Several of these changes were in highly conserved regions and are similar to those that cause sulfa resistance in other organisms. These data suggest that the human-derived P. carinii DHPS may be evolving under positive selective pressure from sulfa drugs.
Collapse
Affiliation(s)
- B R Lane
- Department of Epidemiology, University of Michigan, Ann Arbor 48109-2029, USA
| | | | | | | | | | | | | |
Collapse
|
12
|
Lane BR, Mesquita ON, Meyers SR, Gollub JP. Probability distributions and thermal transport in a turbulent grid flow. ACTA ACUST UNITED AC 1993. [DOI: 10.1063/1.858564] [Citation(s) in RCA: 19] [Impact Index Per Article: 0.6] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/15/2022]
|